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AbstrACt
Introduction The clinical characteristics of autoantibody-
mediated autoimmune diseases are diverse. Yet, medical 
treatment and the associated complications are similar, 
that is, the occurrence of long-term side effects and 
the problem that a significant proportion of patients are 
non-responders. Therefore, new therapeutic options are 
needed. Bortezomib, a proteasome inhibitor, is effective 
in the treatment of multiple myeloma and data from 
experimental models and case reports suggest an effect 
in the treatment of autoantibody-mediated autoimmunity. 
In our study, we will determine the effect of bortezomib 
treatment on a shared surrogate parameter for clinical 
efficacy, namely change in autoantibody levels, which we 
chose as primary parameter.
Methods and analysis We designed a phase IIa trial with 
altogether n=18 treatment-refractory patients suffering 
from myasthenia gravis, systemic lupus erythematosus 
and rheumatoid arthritis that will be treated with 
bortezomib add-on to pre-existing therapy. Primary 
endpoint is the change in autoantibody levels 6 months 
after therapy. Secondary endpoints include concomitant 
medication, disease-specific clinical scores and measures 
of quality of life and activities of daily living.
Ethics and dissemination Safety parameters include 
neurophysiological and clinical signs of peripheral 
neuropathy as well as potential central nervous 
system side effects determined by olfactory and 
neuropsychological testing. The study has been approved 
by the local ethical committee and first participants have 
already been enrolled. This proof of concept study will 
contribute to improve our understanding of plasma cell-
specific treatment approaches by assessing its safety and 
efficacy in reducing serum levels of antibodies known to 
mediate autoimmune disorders. We plan to publish the 
final results of our study in a peer reviewed journal and to 
present our findings at international conferences.
trial registration number NCT02102594.
IntroduCtIon 
In spite of a diversity of clinical manifesta-
tions, a number of autoimmune diseases are 
characterised by a common pathophysiology 
with the production of pathogenic autoanti-
bodies leading to an autoimmune attack on 
various body sites such as neuromuscular 
synapse, kidneys or joints.1–3 Treatment of 
autoantibody-mediated autoimmunity is 
similar across different medical fields and 
mainly relies on corticosteroids and addi-
tional immunosuppressive drugs like azathi-
oprine, mycophenolate acid, cyclosporine 
and others. In recent years, the spectrum 
of available treatments has further been 
expanded by therapeutic antibodies targeting 
for example B cells or cytokines.4–6 However, 
current therapy often leads to unwanted 
side effects and still a significant fraction of 
patients do not respond adequately. Accord-
ingly high-disease activity persists. This is 
probably due to the fact that especially 
so-called long-lived plasma cells are resistant 
to most current therapeutic options except 
autologous stem cell transplantation which 
is reserved for desperate cases.7 In spite of 
immunosuppressive therapy, these contin-
uously antibody producing cells persist 
for years or even decades and are mainly 
strengths and limitations of this study
 ► Our novel study design permits us to include three 
different autoantibody-mediated autoimmune dis-
eases by using the change in autoantibody levels as 
shared primary endpoint.
 ► This proof of concept study with small patient 
groups aims at generating data supporting a larger 
phase III trial.
 ► Safety measurements include a detailed neurophys-
iological and neuropsychological assessment in or-
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responsible for disease chronicity and severity. Thus, 
there is a strong medical need for new therapeutic option 
alternatives concerning these diseases.
Bortezomib (Velcade) has been approved for the treat-
ment of multiple myeloma (plasmocytoma).8 Its mecha-
nism of action, the inhibition of the proteasome, leads 
to apoptosis in cells that have a high-protein turnover 
like for example tumour and myeloma cells.9 Impor-
tantly, plasma cells, having a high-protein turnover due 
to constant secretion of antibodies, are sensitive to borte-
zomib. In line with this, recent studies in experimental 
models show significant effects of bortezomib on autoan-
tibody-mediated autoimmune diseases like systemic lupus 
erythematosus (SLE) or myasthenia gravis (MG).10–12 
Furthermore, recent reports on case series’ of bortezo-
mib-treated SLE and NMDA enzephalitis patients support 
a beneficial role for bortezomib in the treatment of auto-
antibody-mediated autoimmunity.13 14 A recent multi-
centre double-blind trial initiated to assess the effect of 
bortezomib in SLE could not report conclusive results 
with respect to efficacy, as discontinuation due to adverse 
events was extremely high.15 Yet, a prospective study 
investigating bortezomib in different forms of autoanti-
body-mediated autoimmunity in humans has never been 
conducted so far.
We postulate that bortezomib reduces plasma cell 
numbers and autoantibody production irrespective of 
specific antibody target or disease. Reduction of antibody 
levels should reduce disease activity in therapy-refractory 
patients suffering from antibody-mediated autoimmune 
diseases such as MG, SLE and anticitrullinated peptide/
protein antibodies (ACPA)-positive rheumatoid arthritis 
(RA).
These diseases have in common, that specific antibodies, 
that is, antiacetylcholine receptor (AChR), anti-double-
stranded DNA (anti-ds-DNA) and ACPA, are not only 
diagnostic markers. They can also be used for measuring 
disease activity and therapeutic success, that is, clinical 
improvement that is intraindividually correlated with a 
reduction in respective autoantibody serum levels.16–23 
Consequently, therapeutic measures for the treatment of 
acute disease relapses include plasmapheresis or immun-
adsorption aiming at a fast reduction of antibody levels.
MEthods And AnAlysIs
objective
The goal of the TAVAB-trial is to examine the safety and 
therapeutic efficacy of bortezomib in patients with auto-
antibody-mediated autoimmune diseases refractory to 
currently available therapy. Our hypothesis is that borte-
zomib leads to a significant reduction in antibody titres, 
thus resulting in clinical improvement. Furthermore, a 
disease selective analysis of the effects of bortezomib will 
allow us to get knowledge of potential disease-specific 
effects. Depending on the results of this trial, a confirma-
tory phase III study can be envisioned.
study design
The TAVAB trial is an investigator-initiated, prospective, 
unicentric, non-randomised, non-placebo controlled, 
one-armed proof-of-concept study. Altogether 18 patients, 
that is, n=6 suffering from MG, SLE and RA refractory to 
current standard treatment strategies will be treated in 
an add-on manner with bortezomib. Bortezomib will be 
applied in two treatment cycles with four subcutaneous 
injections of 1.3 mg bortezomib/m2 body surface. In the 
case of hepatic insufficiency or peripheral neuropathy, 
the drug dose will be reduced according to the manu-
facturer’s specifications. For prevention of herpes virus 
reactivation or Pneumocystis jerovici, during the borte-
zomib cycles and an additional period of 3 weeks, treat-
ment of patients with 200 mg of aciclovir daily and 960 mg 
of trimethoprim/sulfamethoxazol three times a week is 
mandatory.
In between the two treatment cycles, there is a time 
interval of 10 days. The first follow-up visit is scheduled 10 
days after the last bortezomib application, then monthly 
follow-up visits are scheduled for another 6 months. This 
is followed by two optional follow-up visits in 6-month 
intervals. The following parameters will be measured: 
vital signs, basic clinical status, concomitant medication, 
current disease-specific symptoms and scores, quality of 
life and activities of daily living scores, basic laboratory 
parameters, disease-specific antibody titres (anti-AChR, 
anti-ds-DNA, anti-ACPA), protective antibody serum 
levels (measles, tetanus, diphtheria and mumps), signs for 
an affection of the central or peripheral nervous system, 
adverse events and specific immunological parameters, 
eg, numbers of circulating plasma cells/blasts and the 
distribution of B cell, CD4 and CD8 T cell and dendritic 
cell subsets (see figure 1).
Patient and public involvement
The study was designed based on the need for new ther-
apeutic options for autoantibody-mediated autoimmune 
diseases in patients refractory to standard treatment. 
Patient-oriented secondary endpoints include question-
naires assessing disease-specific quality of life and activi-
ties of daily living. Patients were not actively involved in 
the study design, recruitment or conduct. After final anal-
ysis, study results will be explained to study participants 
on request.
There was no public involvement in the study design.
Inclusion and exclusion criteria
Inclusion criteria
For group I (MG)
 ► Confirmed diagnosis of MG, according to the guide-
lines of the Deutsche Gesellschaft für Neurologie.
 ► Only treatment-refractory patients with significant 
disease activity (eg, QMG of ≥10 at screening) will 
be included, for example, at study entry a long-term 
immunosuppressive therapy excluding corticoster-
oids such as azathioprine or mycophenolat mofetil 
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if the patient does not take any immunosuppressive 
therapy at study entry, at least one type of immuno-
suppression must have been used in the past that had 
been stopped due to inefficacy or side effects.
 ► The patient must have been hospitalised at least once 
in the past for the administration of immunoglobulins 
or plasma exchange therapy due to myasthenic crisis.
 ► Detection of anti-AchR antibodies in serum at study 
entry.
 ► At the time point of administration of bortezomib, 
there must be a minimum interval of 1 month to the 
last administration of immunoglobulins or plasma 
exchange.
For group II (SLE)
 ► Confirmed diagnosis of SLE based on American 
College of Rheumatology (ACR) criteria.
 ► Detection of anti-dsDNA antibodies in serum.
 ► Classification into ‘therapy refractory’ is defined by 
elevated disease activity measured by an SLE Disease 
Activity Index (SLEDAI) score ≥8 in spite of immuno-
suppression (intravenous cyclophosphamide, azathio-
prine or mycophenolat mofetil in standard dosage for 
more than 3 months).
 ► At the time point of administration of bortezomib, 
there must be a minimum interval of 3 months to 
the last administration of high-dose corticosteroid 
therapy or plasma exchange.
For group III (RA)
 ► Confirmed diagnosis of RA based on EULAR/ACR 
criteria.
 ► Classification into ‘therapy refractory’ is defined by a 
significant disease activity for at least 6 months with a 
Disease Activity Score 28 (DAS-28)≥3.2, in spite of at 
least two disease modifying anti rheumatic drugs in 
the past.
 ► Detection of Rheumatoid factor and/or ACPA anti-
bodies in serum.
 ► At the time point of administration of bortezomib, 
there must be a minimum interval of 3 months to 
the last administration of high-dose corticosteroid 
therapy or plasma exchange.
For all groups
 ► Age from 18 to 75 years at screening.
 ► Able and willing to provide informed consent.
 ► If in reproductive age, patients and their respective 
partners must use a highly effective contraceptive 
method, alternatively an abstinence of heterosexual 
activity must be confirmed.
 ► Negative urine pregnancy test at screening (if 
applicable).
Exclusion criteria
For group I (MG)
History of thymectomy less than 1 year before study 
entry.
For group III (RA)
 ► Application of intra-articular or systemic corticoster-
oids for the treatment of an acute exacerbation within 
the last 4 weeks before screening if not administered 
in the frame of a regular therapeutic regimen.
Figure 1 Intervention and visit schedule for the TAVAB trial. AdL, activities of daily living;  NP-testing,  
neuropsychological testing; PNP testing, clinical examination for signs of polyneuropathy, that is, examination of tendon reflexes, 
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 ► Tumour necrosis factor-alpha blockade within the last 
3 months before screening.
 ► Tocilizumab therapy within the last 3 months before 
screening.
 ► Abatacept therapy within the last 3 months before 
screening.
For groups I–III
 ► B-cell-depletion therapy in the past 9 months.
 ► Renal insufficiency with a glomerular filtration rate 
lower than 40 mL/min.
 ► Congestive heart failure with a confirmed left 
ventricular ejection fraction <40%.
 ► Uncontrolled cardiac arrhythmia.
 ► Elevated pulmonal arterial pressure >50 mm Hg, 
TLCO/VA <40%.
 ► Liver cirrhosis (child A, B or C).
 ► Pre-existing sensory or motoric polyneurop-
athy ≥grade 2 according to NCI CTC AE criteria 
within 14 days before study entry.
 ► Signs of a herpes zoster reactivation at study entry or 
history of severe reactivation, that is, involving eye, 
ear, brain or a large body surface.
 ► Persons with either a currently active systemic infec-
tion or with history of a severe viral infection (CMV, 
EBV) in the past 6 months before screening.
 ► Active hepatitis B and/or C or known HIV infection.
 ► Current or past (up to 5 years before study entry) 
malignancy, except multiple myeloma, thymoma/
thymic-carcinoma.
 ► Known bortezomib, trimethoprim/sulfamethoxazol, 
aciclovir allergy or intolerance.
 ► Patients with a clinically significant liver, kidney or 
bone marrow dysfunction defined by the following 
laboratory values at screening.
 – Haemoglobin <8.5 g/L.
 – White cells count <2.5×109/L .
 – Thrombocytes <100/nL.
 – ASAT/ALAT >3.5 x higher than upper reference 
values, except in the case of an SLE relapse or as 
side effect of ongoing medication with for exam-
ple, azathioprin.
 – Bilirubin >2.0 mg/dL.
 ► Pregnancy or breast feeding.
 ► Presence of any comorbidity, which in the opinion of 
the principal investigator could significantly decrease 
the ability of the patient to tolerate the planned 
therapy.
 ► Any medical, psychiatric or other condition, that 
significantly limits the patient’s capability to under-
stand the patient information, to declare informed 
consent, to comply with the study protocol or to 
complete the study.
 ► Patients who are imprisoned or institutionalised.
 ► Missing permission to save and process pseudonymised 
data in the study.
 ► Current or past (last 3 months) participation in 
another interventional study.
Primary and secondary endpoints
The primary endpoint is defined as the change in serum 
concentration of the respective pathogenic antibody in 
each of the examined diseases (ie, anti-AChR in MG, anti-
dsDNA in SLE and anti-ACPA in RA) after bortezomib 
treatment. More precisely, the intraindividual relative 
change in serum titres comparing measurement before 
first application of bortezomib to values 6 month after 
the treatment (V16) is calculated. All antibody titres are 
measured by ELISA in a clinical laboratory with official 
accreditation for these tests.
Secondary endpoints include the change in specific 
autoantibody titres measured before treatment compared 
with multiple time points in the course of the study. Clin-
ical parameters are based on a regular physical examina-
tion as well as disease-specific clinical scores. In detail, 
these are the MGFA classification at the time of presen-
tation, QMG Score, SLEDAI Score, BILAG Score, SLE 
Responder Index, RA DAS-28 and ACR Response Criteria. 
Furthermore, secondary endpoints include disease-spe-
cific assessment of Quality of Life and Activities of Daily 
Living by MG-Qol, MG-ADL, Lupus-Qol, RA-Qol, HAQ 
(Health assessment questionnaire) for SLE and RA. Addi-
tionally, comedication is analysed and treatment effects 
on global humoral immunity are measured by analysis of 
protective antibody titres.
Furthermore, a detailed monitoring of changes of 
a variety of immunological parameters, for example, 
number of activated plasma cells, distribution of B cell, 
CD4 and CD8 T cell and dendritic cell subsets and concen-
trations of soluble mediators is included in the study.
statistical methods
The trial is designed as proof of concept study and does 
not aim at detecting a statistically significant clinical 
efficacy with respect to disease-specific scores. However, 
the primary hypothesis considers antibody serum levels 
as surrogate parameter for changes in intraindividual 
disease activity, which is expected to be significantly 
reduced by bortezomib. A further aim is to gather data in 
order to enable a power analysis and sample size planning 
for a later phase III trial proving the capacity of borte-
zomib in improving clinical outcome.
Relative change of the disease-specific antibody serum 
levels compared 6 months before and after completion of 
bortezomib treatment was defined as primary endpoint. 
As for all the diseases in the focus of this study, antibody 
levels are considered as surrogate parameter for clinical 
activity, for each individual patient, the relative change 
is calculated and the statistical analysis of the primary 
endpoint does not discriminate between the three 
diseases.
Altogether, 18 patients will be enrolled in the study. 
With respect to data from a case series of SLE patients 
treated with bortezomib, we expect a mean reduc-
tion of pathogenic antibody titre of around 60% (SD 
20%). This equals an effect size of 3. With this assump-
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significant reduction should be detectable (two-sided 
testing, alpha=0.05, paired t test and power 99%).
Secondary endpoints are expected changes in the 
following parameters:
 ► (a reduction in) disease severity (clinical score).
 ► (an increase in) quality of life (QoL-score).
 ► (an increase in) abilities concerning activities of daily 
living (AdL-score).
 ► (a reduction in) dosage of immunosuppressive 
comedication.
 ► (a reduction in) protective antibodies (mumps, 
measles, rubella, VZV, pneumococci, CMV).
 ► (a reduction in) autoantibody titres at all single 
time points during and after completion of borte-
zomib administration as compared with baseline.
 ► (a reduction in) numbers of antibody producing plas-
mablasts/cells and concentration of soluble media-
tors in peripheral blood.
The aforementioned secondary endpoints are meas-
ured at multiple time points after bortezomib application 
and changes are determined in comparison to before 
start of treatment. All parameters are analysed for the 
specific diseases in an explorative fashion.
The descriptive analysis of secondary endpoints for the 
single time points is conducted by the determination of 
mean values and SD in the case of normally distributed 
data or alternatively by median and interquartile ranges.
Safety
Safety monitoring includes vital signs, clinical examina-
tion for signs of polyneuropathy, that is, examination of 
tendon reflexes, examination of the sensory system and 
motor examination, ECG, routine laboratory analysis 
and registration of adverse events. Neurophysiological 
measurement of nerve conduction, assessment/evalua-
tion of olfactory function and neuropsychological testing 
before and after completed bortezomib administration 
specifically aims at detecting an affection of the periph-
eral or central nervous system.
Dissemination
The study protocol is published in this journal. Inde-
pendent of study outcome the final results will be made 
available to the public in a peer-reviewed, international 
journal.
dIsCussIon
Current therapeutic options for autoantibody-mediated 
autoimmunity are not able to directly attack the main 
culprit for disease pathogenesis and chronicity, namely 
the autoantibody producing plasma cell.7 Yet, based on 
its mechanism of action,9 experimental evidence10–12 
and case reports,13 14 we believe that bortezomib might 
offer an interesting new therapeutic option. Thus, we 
have initiated the TAVAB trial, aiming to investigate the 
therapeutic potential of inhibition of the proteasome by 
bortezomib in severely affected MG, SLE and RA patients 
refractory to standard therapy. One special aspect of this 
study is that we are testing a new treatment alternative 
in three different indications using a primary endpoint 
relevant to all three diseases. This is only possible, as the 
three diseases have in common that antibody levels can 
be regarded as surrogate parameter for clinical disease 
severity.16–26 By determining relative changes of autoanti-
body serum levels before and after bortezomib therapy, we 
can calculate data from all included patients to prove the 
efficacy of our drug with respect to the primary endpoint 
of our study regardless of the individual disorder.
In contrast to our first study in SLE13 15 and as sole alter-
ation to the usual protocol for the treatment of MM with 
bortezomib, we do not co-administer dexamethasone to 
our patients. The reason for this is that we want to rule out 
that changes in serum antibody titre are caused rather by 
dexamethasone than by bortezomib itself. In general, we 
use a protocol comparable to the study by Ishii et al15 that 
has recently reported a high drop-out rate due to side 
effects. It remains to be seen whether our study will be 
affected by a similar drop-out rate and whether this could 
be an SLE-specific problem.
In the meantime, the study has already started, enrol-
ment for SLE and MG patients is as expected and the 
envisioned enrolment numbers for these two indications 
should be fulfilled in 2018. However, so far we are unable 
to include any RA patient in our study, even after changing 
our inclusion criteria for RA patients. This might be due 
to the fact, that new treatment options, that is, JAK inhibi-
tors, have been approved for the treatment of RA.
In order to overcome this problem, we have changed 
our study protocol in accordance with the responsible 
regulatory institutions. We have decided to keep the total 
number of 18 patients constant; however, we will now 
include patients with either MG, SLE or RA on a first-
come first-serve basis. This will result in more patients with 
MG and SLE, while the number of included RA patients 
will be lower. In the most extreme scenario, no RA patient 
will be included and therefore RA disease-specific effects 
of bortezomib will be difficult to estimate. Yet, by keeping 
the total number of included patients constant, we will 
still be able to analyse safety and therapeutic efficacy of 
bortezomib in patients with autoantibody-mediated auto-
immune diseases in general. As the number of borte-
zomib-treated MG and SLE patients in our new study 
protocol is increased, we have the possibility to reveal 
specific effects for these diseases on an even stronger 
basis. Certainly, the small number of included patients 
might still be limiting.
Bortezomib has already been used for treatment of 
multiple myeloma for several years; therefore, poten-
tial side effects are quite well known. Consequently, the 
treating physicians and affected patients have the possi-
bility to estimate the potential benefit of treatment rela-
tive to the risk of potential side effects. Due to the current 
experiences with this substance, we assume that especially 
a peripheral neuropathy and a reactivation of herpes 
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bortezomib induced neuropathy is often reversible27–29 
and in less severe cases even a dose adjustment is suffi-
cient for the prevention of long-lasting nerve damage. 
Reactivation of herpes virus should be preventable by 
prophylactic treatment with aciclovir incorporated in our 
study design.
In our study, we have included two tests in order to 
specifically monitor effects of bortezomib on the central 
nervous system. For this purpose, we will evaluate olfac-
tory and neuropsychological performance before and 
after bortezomib administration. All in all, during the 
whole study, the patients are carefully monitored for side 
effects and therefore we believe that the risk of serious 
long-lasting side effects is acceptably low.
In conclusion, we consider our study to provide a good 
chance for paving the way for novel therapeutic strate-
gies in autoantibody-mediated disorders. Patients to be 
included in our study are afflicted with a severe course 
of chronic disorder often needing frequent hospitalisa-
tions and impairing patients’ quality of life dramatically. 
These patients are usually treated on a long term with 
the current standard therapy sometimes accompanied by 
(severe) side effects. We do not aim at proving a signifi-
cant clinical improvement in this study. Yet, we consider 
our primary endpoint, which is a significant intraindi-
vidual reduction of autoantibody serum levels through 
bortozomib application, important to judge whether 
bortezomib has the capacity to improve the clinical course 
in autoantibody-mediated disorders. Consequently, our 
study will hopefully enable us to justify and plan a phase 
III clinical trial to prove the efficacy of bortezomib in the 
treatment of MG, RA and SLE.
trial status
The current protocol (V.1.4) was approved on 24 August 
2017. The first protocol version had been approved on 17 
July 2014. Study recruitment began on 31 October 2014 
and is expected to be completed by June 2019.
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